Safety Data Exchange Agreements: The PV Obligation No Licensing Deal Gets Right

Pharmacovigilance obligations travel with products, not with companies. That principle sounds straightforward, but the contractual architecture that governs how safety data moves between licensors, licensees, co-development partners, and contract organisations remains one of the most persistently mismanaged areas of pharmaceutical compliance. Safety Data Exchange Agreements, commonly abbreviated as SDEAs, and sometimes referred to as Pharmacovigilance Agreements or PV Agreements, are the mechanism through which these obligations are allocated, documented, and fulfilled. They are also, in practice, one of the most commonly deficient documents audited by regulatory authorities.

The pattern is consistent across deal types: licensing negotiations focus on commercial terms, exclusivity provisions, milestone payments, and IP protections. When pharmacovigilance comes up at all, it is often addressed with a brief clause committing both parties to “comply with applicable PV regulations,” a statement that satisfies no regulatory requirement and provides no operational clarity. By the time the product reaches the market, both parties may discover that their SAE reporting timelines are misaligned, their signal management responsibilities are undefined, and their PSUR/PBRER obligations conflict.

Regulatory consequences follow. The EMA, FDA, MHRA, TGA, and most other major agencies have cited inadequate SDEAs in inspection findings and warning letters. The obligation is clear; the execution is where deals consistently fall short.

What a Safety Data Exchange Agreement Is and What It Must Do

An SDEA is a binding contractual document that defines how two or more parties involved in the development, manufacturing, or commercialisation of a medicinal product will share and manage individual case safety reports (ICSRs), aggregate safety data, safety signals, Risk Management Plans, and other pharmacovigilance obligations.

The regulatory basis for SDEAs derives from multiple sources. In the EU, Article 25 of Commission Implementing Regulation (EU) No 520/2012 explicitly requires marketing authorisation holders who share responsibilities with other parties to have written agreements in place describing their respective pharmacovigilance obligations. EMA’s Good Pharmacovigilance Practices (GVP) Module I reinforces this, and GVP Module VI details ICSR-related arrangements. FDA’s safety reporting regulations under 21 CFR Part 314 (drugs) and 21 CFR Part 600 (biologics) similarly presuppose clear delineation of safety reporting responsibilities between applicants and partners.

Want to read the complete article?

This is an abridged version of the full blog. For the complete breakdown of SDEA requirements, regulatory expectations, and common compliance pitfalls, visit:

🔗 **Read More**